Dashboard
Manage Tickers

TNGXTango Therapeutics, Inc.

Nasdaq tangotx.com


$ 7.07 $ -0.30 (-4.06 %)    

Thursday, 23-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -2.05 (-0.45 %)
DIA $ 398.57 $ -6.00 (-1.51 %)
SPY $ 530.36 $ -3.87 (-0.73 %)
TLT $ 91.26 $ -0.59 (-0.64 %)
GLD $ 225.37 $ -4.39 (-1.99 %)
$ 7.09
$ 6.81
$ 0.00 x 0
$ 0.00 x 0
$ 6.63 - $ 7.66
$ 2.47 - $ 13.03
1,224,383
na
766.94M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-27-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity
Tango Therapeutics Shuts Early-Stage Cance...
05/23/2024 16:53:11

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

wedbush-maintains-outperform-on-tango-therapeutics-lowers-price-target-to-11
Wedbush Maintains Outperform on Tango Ther...
05/23/2024 16:35:58

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
05/23/2024 12:06:48

tango-therapeutics-shares-are-trading-lower-after-the-company-announced-the-discontinuation-of-its-tng348-program
Tango Therapeutics shares are trading lowe...
05/23/2024 11:02:42

tango-therapeutics-reports-discontinuation-of-tng348-program-says-grade-34-liver-function-abnormalities-were-observed-in-patients-remaining-on-study-longer-than-eight-weeks
Tango Therapeutics Reports Discontinuation...
05/23/2024 11:01:44

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...

hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-17-price-target
HC Wainwright & Co. Reiterates Buy on Tang...
05/09/2024 11:16:18

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...

tango-therapeutics-cash-position-of-344m-as-of-march-31-2024-cash-runway-into-late-2026-expected
Tango Therapeutics' Cash Position Of $344M...
05/08/2024 11:36:34

tango-therapeutics-q1-2024-gaap-eps-035-misses-031-estimate-sales-6471m-miss-6669m-estimate
Tango Therapeutics Q1 2024 GAAP EPS $(0.35...
05/08/2024 11:35:50

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of ...

cantor-fitzgerald-initiates-coverage-on-tango-therapeutics-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On Ta...
04/04/2024 11:02:20

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating.

hc-wainwright--co-maintains-buy-on-tango-therapeutics-raises-price-target-to-17
HC Wainwright & Co. Maintains Buy on Tango...
03/20/2024 10:56:13

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price targ...

recap-tango-therapeutics-q4-earnings
Recap: Tango Therapeutics Q4 Earnings
03/18/2024 14:05:06

tango-therapeutics-cash-position-of-337m-as-of-december-31-2023-combined-with-42m-in-proceeds-from-atm-in-january-2024-is-expected-to-provide-cash-runway-into-late-2026
Tango Therapeutics' Cash Position Of $337M...
03/18/2024 11:44:29

tango-therapeutics-q4-gaap-eps-032-misses-028-estimate-sales-543m-miss-824m-estimate
Tango Therapeutics Q4 GAAP EPS $(0.32) Mis...
03/18/2024 11:43:25

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of ...

piper-sandler-initiates-coverage-on-tango-therapeutics-with-overweight-rating-announces-price-target-of-18
Piper Sandler Initiates Coverage On Tango ...
02/12/2024 11:43:17

Piper Sandler analyst Joseph Catanzaro initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and a...

medivirs-licensee-tango-therapeutics-dosed-the-first-patient-with-tng348-a-novel-usp1-inhibitor
Medivir's Licensee, Tango Therapeutics Dos...
01/04/2024 07:59:54

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas o...

tango-therapeutics-says-first-patient-dosed-in-phase-12-trial-of-tng348-in-patients-with-brca12-mutant-and-other-hrd-cancers
Tango Therapeutics Says First Patient Dose...
01/03/2024 12:03:28

b-riley-securities-initiates-coverage-on-tango-therapeutics-with-buy-rating-announces-price-target-of-16
B. Riley Securities Initiates Coverage On ...
12/08/2023 11:10:24

B. Riley Securities analyst Yuan Zhi initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces ...

tango-therapeutics-q3-earnings-insights
Tango Therapeutics: Q3 Earnings Insights
11/08/2023 12:45:06

tango-therapeutics-q3-cash-position-of-360m-provides-cash-runway-into-2026
Tango Therapeutics' Q3 Cash Position Of $3...
11/08/2023 12:16:45

tango-therapeutics-q3-eps-023-beats-034-estimate-sales-1073m-beat-732m-estimate
Tango Therapeutics Q3 EPS $(0.23) Beats $(...
11/08/2023 12:15:23

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION